Hepatocellular Carcinoma (HCC) Drug Market in China 2021

March 2021 | 21 pages | ID: H4E6B86A15C3EN
StrategyHelix Inc

Abstracts

The hepatocellular carcinoma (HCC) drug market in China in terms of revenue is set to grow by US$ 4 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 21.7% during the forecast period, according to data and analytics company StrategyHelix.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for hepatocellular carcinoma (HCC) drug. The China hepatocellular carcinoma (HCC) drug market is segmented on the basis of region. By region, it is categorized into Central South China, East China, North China, Northeast China, Northwest China, and Southwest China.

The report has profiled some of the key players of the market such as Bayer AG, Eisai Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd..

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the hepatocellular carcinoma (HCC) drug market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope
Region: Central South China, East China, North China, Northeast China, Northwest China, and Southwest China
Years Considered: this report covers the period 2017 to 2027

Key Benefits for Stakeholders
Get a comprehensive picture of the China hepatocellular carcinoma (HCC) drug market
Pinpoint growth sectors and trends for investment
Understand what the future of the hepatocellular carcinoma (HCC) drug market in China looks like
Identify the competitive landscape and window of opportunity

Contents

1. MARKET DEFINITION

2. RESEARCH METHODOLOGY

3. MARKET DATA & OUTLOOK

3.1 Market Value
3.2 Market Value Forecast

4. HEPATOCELLULAR CARCINOMA (HCC) DRUG MARKET BY REGION

4.1 Central South China
4.2 East China
4.3 North China
4.4 Northeast China
4.5 Northwest China
4.6 Southwest China

5. COMPANY PROFILES

5.1 Bayer AG
5.2 Eisai Co., Ltd.
5.3 Jiangsu Hengrui Medicine Co., Ltd.

6. APPENDIX

6.1 About StrategyHelix
6.2 Disclaimer